All rights reserved.”
“PURPOSE: To evaluate the efficacy and safety of capturing the intraocular lens (IOL) optic through the anterior capsulorhexis opening in eyes with multifocal IOLs and a residual refractive error.
SETTING: Hospital Oftalmologico de Brasilia,
Brasilia, Brazil.
METHODS: Eyes with previous cataract surgery and Tecnis ZM900 multifocal IOL implantation were prospectively analyzed. After at least 1 month, patients had second surgery in which the NSC23766 ic50 IOL optic was captured through the anterior capsulorhexis opening to correct the residual refractive error. Preoperative and postoperative examinations at 1 day and 3 months included spherical equivalent (SE); uncorrected distance (UDVA), near (UNVA), and intermediate (UIVA) visual acuities; and selleck products corrected distance visual acuity (CDVA).
RESULTS: The study included 16 eyes of 14 patients. The mean UDVA was 0.32 logMAR preoperatively and 0.10 logMAR after anterior optic capture and the mean SE, +1.09 diopters (D) and +0.26 D, respectively; both improvements were statistically significant (P<.001). The change in CDVA and UNVA from before anterior optic capture to the last follow-up was not statistically significant. The UIVA was significantly worse postoperatively (P = .011). No eye lost lines of CDVA. One eye (6.25%) developed glaucoma postoperatively. At the last follow-up, 13 patients (92.85%) were spectacle-independent
for near and distance vision.
CONCLUSION: Early outcomes indicate find more that anterior optic capture is a safe, accurate procedure in eyes with multifocal IOLs and a mild hyperopic residual refractive error postoperatively.”
“Objective To evaluate the efficacy, tolerability, and pharmacokinetics of bicalutamide plus anastrozole in young males with testotoxicosis
Methods This was a multicenter, open-label, single-arm, 12-month, Phase II pilot trial in 14 males (2-9 years) with testotoxicosis treated with bicalutamide (12 5, 25, 50, or 100 mg) and anastrozole (0 5 or 1 mg) daily The primary outcome was change in growth rate
Results At 1 year, the mean (standard deviation) change from baseline in growth rate was -1 6 (+/- 5 1) cm/year and
-0 1 (+/- 1 8) SD units, and in bone maturation was -2 3 (+/- 0 5) years The bone age/chronological age ratio was reduced from 2 1 ( 0 6) at baseline to 1 0 (+/- 0 4) (p = 0 00013) Steady-state trough R-bicalutamide and anastrozole concentrations were attained by Day 21 and 8, respectively Gynecomastia (42 9%) and breast tenderness (12 5%) were the most common treatment-related adverse events
Conclusions Treatment of testotoxicosis with bicalutamide plus anastrozole resulted in slower growth rate”
“PURPOSE: To compare 2 sequences of combined intrastromal corneal ring segment (ICRS) implantation and ultraviolet/riboflavin-mediated corneal collagen crosslinking (CXL) in progressive keratoconus. SETTING: Dunya Eye Hospital, Istanbul, Turkey.